Bayer hosted an investor webinar on February 6, 2026, live from ISC 2026 in New Orleans, to discuss the results of the OCEANIC-STROKE Phase III trial and the potential of asundexian in secondary stroke prevention.
Key Speakers and Agenda
Alexander Siedler from Bayer’s Investor Relations led the session. He introduced the expert panel, highlighting the focus on unmet needs in secondary stroke prevention.
Christoph Koenen, Head of Clinical Development and Operations at Bayer Pharmaceuticals, provided an overview of persistent challenges in this medical area.
Ashkan Shoamanesh, Professor of Neurology at McMaster University in Canada and one of the trial’s principal investigators, presented the trial data. He expressed confidence in the positive outcomes during the discussion.
Jan Voss, Global Head for Asundexian at Bayer, addressed ongoing health economic issues in secondary stroke prevention and explored how asundexian could offer a viable solution moving forward.
Analyst Participation
The webinar also featured insights from leading analysts, including Sachin Jain from BofA Securities Research Division, James Quigley from Goldman Sachs Research Division, Richard Vosser from JPMorgan Chase & Co Research Division, Charles Pitman from Barclays Bank PLC Research Division, Alek Ebbeling from UBS Investment Bank Research Division, and Rajesh Kumar from HSBC Global Investment Research.
The one-hour session aimed to deliver comprehensive updates on Bayer Aktiengesellschaft (BAYRY) advancements in stroke prevention therapies.
